The societal costs of insomnia

Alan G Wade, Alan G Wade

Abstract

Objective: Insomnia can be broadly defined as difficulty initiating or maintaining sleep, or sleep that is not refreshing or of poor quality with negative effect on daytime function. Insomnia can be a primary condition or comorbid to an underlying disorder. Subjective measures of insomnia used in population studies, usually based on complaints of unsatisfactory sleep, put the prevalence at about 10%. Insomnia is more common in the elderly and in women, and is often associated with medical and psychiatric disorders. This review examines the measures used to assess quality of sleep (QOS) and daytime functioning and the impact of insomnia on society using these measures.

Methods: Literature searches were performed to identify all studies of insomnia (primary and comorbid) in adults (aged 18-64 years) and the elderly (aged ≥ 65 years) with baseline and/or outcomes relating to QOS or daytime functioning. The impact of poor QOS on quality of life (QOL), psychomotor and cognitive skills, health care resource utilization, and other societal effects was examined.

Results: Although definitions and measurement scales used to assess sleep quality vary widely, it is clear that the societal consequences of insomnia are substantial and include impaired QOL and increased health care utilization. The impact of poor QOS and impaired daytime functioning common in insomnia can lead to indirect effects such as lower work productivity, increased sick leave, and a higher rate of motor vehicle crashes.

Conclusions: Insomnia is associated with substantial direct and indirect costs to society. It is almost impossible to separate the costs associated with primary and comorbid insomnia. More studies are required which control for the severity of any primary disorder to accurately evaluate the costs of comorbid insomnia. Development of standardized diagnostic and assessment scales will enable more accurate quantification of the true societal burden of insomnia and will contribute to greater understanding of this disorder.

Keywords: health care resource utilization; insomnia; quality of life; quality of sleep; societal cost.

References

    1. Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM. Recommendations for a standard research assessment of insomnia. Sleep. 2006;29(9):1155–1173.
    1. Chevalier H, Los F, Boichut D, et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol. 1999;13(4 Suppl 1):S21–24.
    1. Hajak G SINE Study Group. Study of Insomina in Europe. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci. 2001;251(2):49–56.
    1. Kryger MH. The burden of chronic insomnia on society. Manag Care. 2006;15(9 Suppl 6):1–5. 17.
    1. Schubert CR, Cruickshanks KJ, Dalton DS, Klein BE, Klein R, Nondahl DM. Prevalence of sleep problems and quality of life in an older population. Sleep. 2002;25(8):889–893.
    1. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004;65(Suppl 8):13–19.
    1. Ohayon MM. Prevalence and comorbidity of sleep disorders in general population. Rev Prat. 2007;57(14):1521–1528.
    1. Roth T, Krystal AD, Lieberman IJ. Long-term issues in the treatment of sleep disorders. Prim Psychiatry. 2007;14:1–16.
    1. Dundar Y, Boland A, Strobl J, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8(24):iii–x. 1–125.
    1. Lichstein KL, Durrence HH, Bayen UJ, Riedel BW. Primary versus secondary insomnia in older adults: subjective sleep and daytime functioning. Psychol Aging. 2001;16(2):264–271.
    1. Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone. 2003;5(3):5–15.
    1. Yook K, Lee SH, Ryu M, et al. Usefulness of mindfulness-based cognitive therapy for treating insomnia in patients with anxiety disorders: a pilot study. J Nerv Ment Dis. 2008;196(6):501–503.
    1. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37(1):9–15.
    1. Specchio LM, Prudenzano MP, de Tommaso M, et al. Insomnia, quality of life and psychopathological features. Brain Res Bull. 2004;63(5):385–391.
    1. Leger D. Public health and insomnia: economic impact. Sleep. 2000;23(Suppl 3):S69–76.
    1. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–10.
    1. Leger D, Guilleminault C, Bader G, Levy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep. 2002;25(6):625–629.
    1. Martikainen K, Partinen M, Hasan J, Laippala P, Urponen H, Vuorii I. The problem of long-term insomnia: a 5-year follow-up study in a middle-aged population. Sleep Hypn. 2001;3(3):97–105.
    1. Roth T. Treatment and management of chronic insomnia. Prim Psychiatr. 2007;14:1–11.
    1. Byles JE, Mishra GD, Harris MA, Nair K. The problems of sleep for older women: changes in health outcomes. Age Ageing. 2003;32(2):154–163.
    1. Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care. 2006;12(Suppl 8):S246–252.
    1. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs. 2007;21(4):319–334.
    1. Harvey AG, Stinson K, Whitaker KL, Moskovitz D, Virk H. The subjective meaning of sleep quality: a comparison of individuals with and without insomnia. Sleep. 2008;31(3):383–393.
    1. Devine EB, Hakim Z, Green J. A systematic review of patient-reported outcome instruments measuring sleep dysfunction in adults. Pharmacoeconomics. 2005;23(9):889–912.
    1. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
    1. Doi Y, Minowa M, Uchiyama M, et al. Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res. 2000;97:2–3. 165–172.
    1. Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med. 2001;63(1):49–55.
    1. Broström A, Stromberg A, Dahlstrom U, Fridlund B. Sleep difficulties, daytime sleepiness, and health-related quality of life in patients with chronic heart failure. J Cardiovasc Nurs. 2004;19(4):234–242.
    1. Le Guen Y, Gagnadoux F, Hureaux J, et al. Sleep disturbances and impaired daytime functioning in outpatients with newly diagnosed lung cancer. Lung Cancer. 2007;58(1):139–143.
    1. Currie SR, Clark S, Hodgins DC, El-Guebaly N. Randomized controlled trial of brief cognitive-behavioural interventions for insomnia in recovering alcoholics. Addiction. 2004;99(9):1121–1132.
    1. Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. Arch Intern Med. 2005;165(21):2527–2535.
    1. Epstein DR, Dirksen SR. Randomized trial of a cognitive-behavioral intervention for insomnia in breast cancer survivors. Oncol Nurs Forum. 2007;34(5):E51–59.
    1. Dixon S, Morgan K, Mathers N, Thompson J, Tomeny M. Impact of cognitive behavior therapy on health-related quality of life among adult hypnotic users with chronic insomnia. Behav Sleep Med. 2006;4(2):71–84.
    1. Guilleminault C, Lin CM, Goncalves MA, Ramos E. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia. J Psychosom Res. 2004;56(5):511–515.
    1. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics. 1998;14(6):629–637.
    1. Iliescu EA, Coo H, McMurray MH, et al. Quality of sleep and health-related quality of life in haemodialysis patients. Nephrol Dial Transplant. 2003;18(1):126–132.
    1. Molnar MZ, Novak M, Szeifert L, et al. Restless legs syndrome, insomnia, and quality of life after renal transplantation. J Psychosom Res. 2007;63(6):591–597.
    1. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep. 1999;22(Suppl 2):S379–385.
    1. Philip P, Leger D, Taillard J, et al. Insomniac complaints interfere with quality of life but not with absenteeism: respective role of depressive and organic comorbidity. Sleep Med. 2006;7(7):585–591.
    1. Saletu B, Prause W, Loffler-Stastka H, et al. Quality of life in nonorganic and organic sleep disorders: I. Comparison with normative data. Wien Klin Wochenschr. 2003;115:7–8. 246–254.
    1. Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83.
    1. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23(10):2597–2605.
    1. Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs. 2008;61(6):664–675.
    1. Ranjbaran Z, Keefer L, Farhadi A, Stepanski E, Sedghi S, Keshavarzian A. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22(11):1748–1753.
    1. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33(2):47–53.
    1. Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry. 1999;60(8):536–544.
    1. Germain A, Moul DE, Franzen PL, et al. Effects of a brief behavioral treatment for late-life insomnia: preliminary findings. J Clin Sleep Med. 2006;2(4):403–406.
    1. Haimov I, Hadad BS, Shurkin D. Visual cognitive function: changes associated with chronic insomnia in older adults. J Gerontol Nurs. 2007;33(10):32–41.
    1. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry. 2000;15(8):704–712.
    1. Jansson M, Linton SJ. Cognitive-behavioral group therapy as an early intervention for insomnia: a randomized controlled trial. J Occup Rehabil. 2005;15(2):177–190.
    1. Lai HL. Self-reported napping and nocturnal sleep in Taiwanese elderly insomniacs. Public Health Nurs. 2005;22(3):240–247.
    1. Leger D, Massuel MA, Metlaine A SISYPHE Study Group. Professional correlates of insomnia. Sleep. 2006;29(2):171–178.
    1. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16(4):372–380.
    1. Lewith GT, Godfrey AD, Prescott P. A single-blinded, randomized pilot study evaluating the aroma of Lavandula augustifolia as a treatment for mild insomnia. J Altern Complement Med. 2005;11(4):631–637.
    1. Lydiard RB, Lankford DA, Seiden DJ, Landin R, Farber R, Walsh JK. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. J Clin Sleep Med. 2006;2(3):309–315.
    1. MacMahon KM, Broomfield NM, Espie CA. Attention bias for sleep-related stimuli in primary insomnia and delayed sleep phase syndrome using the dot-probe task. Sleep. 2006;29(11):1420–1427.
    1. Morin CM, Beaulieu-Bonneau S, LeBlanc M, Savard J. Self-help treatment for insomnia: a randomized controlled trial. Sleep. 2005;28(10):1319–1327.
    1. Nowell PD, Reynolds CF, 3rd, Buysse DJ, Dew MA, Kupfer DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry. 1999;60(2):89–95.
    1. Roth T, Wright KP, Jr, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep. 2006;29(3):335–341.
    1. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28(6):720–727.
    1. Scharf MB, Black J, Hull S, Landin R, Farber R. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep. 2007;30(6):743–752.
    1. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia–a randomized, double-blind, comparative clinical study. Eur J Med Res. 2002;7(11):480–486.
    1. Lis CG, Gupta D, Grutsch JF. The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer. 2008;16(3):261–266.
    1. Chen WC, Lim PS, Wu WC, et al. Sleep behavior disorders in a large cohort of chinese (Taiwanese) patients maintained by long-term hemodialysis. Am J Kidney Dis. 2006;48(2):277–284.
    1. Clark DJ, Fukami N, Gottipati V, et al. Attributes and prevalence of sleep disturbances in hepatitis C patients receiving interferon alph-2b (INF alpha-2b) plus ribavirin using the Sleep Quality Profile (SQP). American Association for the Study of Liver Diseases. Gastroenterology. 2000;118:A143.
    1. Currie SR, Wilson KG, Pontefract AJ, deLaplante L. Cognitive-behavioral treatment of insomnia secondary to chronic pain. J Consult Clin Psychol. 2000;68(3):407–416.
    1. Currie SR, Wilson KG, Curran D. Clinical significance and predictors of treatment response to cognitive-behavior therapy for insomnia secondary to chronic pain. J Behav Med. 2002;25(2):135–153.
    1. Dashevsky BA, Kramer M. Behavioral treatment of chronic insomnia in psychiatrically ill patients. J Clin Psychiatry. 1998;59(12):693–699.
    1. Davidson JR, Waisberg JL, Brundage MD, MacLean AW. Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psychooncology. 2001;10(5):389–397.
    1. Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004;5(1):15–20.
    1. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723–1732.
    1. Rao V, Spiro JR, Samus QM, et al. Sleep disturbances in the elderly residing in assisted living: findings from the Maryland Assisted Living Study. Int J Geriatr Psychiatry. 2005;20(10):956–966.
    1. Scharf MB, McDannold M, Zaretsky N, et al. Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride. Am J Ther. 1999;6(2):77–82.
    1. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51(3):229–235.
    1. LeBlanc M, Beaulieu-Bonneau S, Merette C, Savard J, Ivers H, Morin CM. Psychological and health-related quality of life factors associated with insomnia in a population-based sample. J Psychosom Res. 2007;63(2):157–166.
    1. Schubert CR, Cruickshanks KJ, Dalton DS, et al. Insomnia and quality of life in older adults. Am J Epidemiol. 2001;153:S23.
    1. Bastien CH, Fortier-Brochu E, Rioux I, LeBlanc M, Daley M, Morin CM. Cognitive performance and sleep quality in the elderly suffering from chronic insomnia. Relationship between objective and subjective measures. J Psychosom Res. 2003;54(1):39–49.
    1. Haimov I, Hanuka E, Horowitz Y. Chronic insomnia and cognitive functioning among older adults. Behav Sleep Med. 2008;6(1):32–54.
    1. Crenshaw MC, Edinger JD. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav. 1999;66(3):485–492.
    1. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev. 2004;8(1):63–72.
    1. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep. 1999;22(Suppl 2):S386–393.
    1. Sanford JR. Tolerance of debility in elderly dependants by supporters at home: its significance for hospital practice. Br Med J. 1975;3(5981):471–473.
    1. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793–799.
    1. Menzin J, Lang KM, Levy P, Levy E. A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France. Pharmacoeconomics. 2001;19(1):69–78.
    1. Bolge SC, Doan JF, Kannan H, Baran RW. Understanding primary insomnia in older people. Association of insomnia with quality of life, work productivity, and activity impairment. Nurs Older People. 2009;21(3):30–33.
    1. Nebes RD, Buysse DJ, Halligan EM, Houck PR, Monk TH. Self-reported sleep quality predicts poor cognitive performance in healthy older adults. J Gerontol B Psychol Sci Soc Sci. 2009;64(2):180–187.
    1. Ustinov Y, Lichstein KL, Wal GS, Taylor DJ, Riedel BW, Bush AJ. Association between report of insomnia and daytime functioning. Sleep Med. 2010;11(1):65–68.
    1. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2010;14(1):69–82.
    1. Shekleton JA, Rogers NL, Rajaratnam SM. Searching for the daytime impairments of primary insomnia. Sleep Med Rev. 2010;14(1):47–60.
    1. Léger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379–389.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever